GPC3 targeting peptide 2

GPC3 targeting peptide 2 (ALLANHEELFQT) at 5 μM specifically binds to GPC3 on human Hep3B hepatocellular carcinoma cells; its binding level decreases significantly, by up to 8.7-fold, after GPC3 knockdown^[1].
GPC3 targeting peptide 2 (0-200 μM; 30 min) competes with IRDye800-labeled GPC3 targeting peptide 2 for binding to human Hep3B hepatocellular carcinoma cells in a dose-dependent manner, confirming that this peptide mediates specific binding to GPC3^[1].
GPC3 targeting peptide 2 (0-200 nM; 1 h) binds to human Hep3B hepatocellular carcinoma cells with high affinity, with a dissociation constant (K_d = 39.5 nM) and rapid binding kinetics (0.21 min⁻¹)^[1].
GPC3 targeting peptide 2 (5 μM; 10 min) specifically binds to human hepatocellular carcinoma (HCC) specimens in vitro, exhibits high sensitivity and specificity for distinguishing HCC from non-HCC and liver cirrhosis, and shows strong colocalization with anti-GPC3 antibodies^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.